Chairman Emeritus of Pathology, Cedars Sinai Medical Center - Clinical Professor of Pathology, UCLA - Adjunct Professor of Pathology, Northwestern UniversityBiography
David Engman was born and raised in Des Moines, Iowa in 1961, and received a BA in Biology from Northwestern University in 1983 and MD and PhD (Genetics) degrees from the University of Iowa in 1990. He then joined Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital (NMH) in Chicago as a Resident Physician in Clinical Pathology. Dr. Engman completed residency training on a part-time basis over five years, which allowed him to establish an independent research laboratory as an Assistant Professor, focused on tropical parasitic infections and infection-induced autoimmune myocarditis. By 1995, Dr. Engman had completed clinical training and the Engman Lab had published 22 papers and had earned nearly $700,000 in research grants and fellowships. In 1995, Dr. Engman was appointed attending Molecular Genetic Pathologist at NMH as well as Director of the Northwestern MD-PhD Program (Medical Scientist Training Program - MSTP). He taught microbiology, pathology and genetics to Northwestern medical students, graduate students and undergraduates. Dr. Engman maintained the roles of teacher, mentor, scientist, pathologist and MSTP Director for the next 17 years. In 2011 he stepped down as MSTP Director to become Chief of the Thorson Goodall Diagnostic Molecular Biology Lab at NMH. By the end of his time at Northwestern in 2016, Dr. Engman had trained more than 90 scientists and physician-scientists in his research lab and published nearly 100 research articles and reviews. Grant and fellowship income during his 25 years at Northwestern exceeded $25 million. Finally, Dr. Engman taught nearly 5,000 medical, graduate and undergraduate students and mentored over 200 MSTP students and dozens of junior faculty. In 2015 he was voted Mentor of the Year by the Northwestern Medical School faculty, not only for mentoring so many students and faculty, but also for his specific focus on promoting careers of women and others underrepresented in science and medicine. In 2016, Dr. Engman was recruited to Cedars Sinai Medical Center in Los Angeles to be Chairman of the Department of Pathology and Laboratory Medicine, with a 10-year goal of becoming a top 20 academic department. The department enjoyed tremendous growth in all mission areas under Dr. Engman's leadership. Quality improved significantly and the clinical laboratory was named the #2 hospital lab in the US by Medical Laboratory Observer in 2017. 31 new faculty were recruited from top universities, including a dozen scientists and physician-scientists, and research grant income increased by over $9 million per year to earn a top 25 NIH ranking. Laboratory charges increased by 50% to $1.8 billion with estimated revenues of $405 million (22.5%), while expenses remained steady at $128 million. Clinical outreach income grew by 60% to represent nearly two-thirds of anatomic pathology revenue. Education programs expanded with new fellowships and a Pathologist Scientist Training Program for MD-PhD residents pursuing careers combining research and clinical practice. Between 2016 and 2020, Cedars Sinai Pathology grew to well over 700 individuals, working together toward the missions of excellence in patient care, advances in disease diagnosis and pathogenesis, education of physicians, scientists and clinical laboratory scientists and community service. After essentially accomplishing the goals of the department in 4 years, Dr. Engman retired from Cedars Sinai in January 2020 to pursue his longstanding interest in the biotechnology field, in which he had become increasingly involved during the past decade. He has technical expertise in molecular biology and genetics, biochemistry, structural biology, immunology, and cell and tissue biology and advanced imaging, including all omics. Dr. Engman's areas of clinical expertise include general medicine and pathology and, especially, cancer, infectious disease and heart disease. Finally, his experience leading small, medium and large enterprises, including serving as president of several national organizations, will be valuable as he pursues his next venture.